Using modified stem cells to fight HIV infection
Official title: HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation
Funded at University of California, San Francisco · NIH-10992648 · Data updated 2026-11-12
This study is looking at a new treatment that uses specially modified cells from your own body to help fight HIV and reduce the virus in people who are getting stem cell transplants, and it aims to make this treatment safer and more effective for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | January 13, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $781,939 |
| NIH project number | 5R01AI176951-03 |
| Project ID | NIH-10992648 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who require autologous stem cell transplantation, particularly those with lymphoma.
✕Less likely to help
Patients who are not living with HIV or those who do not require stem cell transplantation may not benefit from this research.
What this research studies
This research investigates the use of autologous gene-modified cells that are resistant to HIV to reduce the viral reservoir in patients. The approach combines multiple anti-HIV genes into a single lentiviral vector, which aims to block HIV infection at various stages of its life cycle. By focusing on a more comprehensive strategy than current methods, this research seeks to provide a stronger defense against HIV for individuals undergoing autologous stem cell transplantation. Patients who participate will be monitored for safety and effectiveness of this innovative treatment.
Why it matters
Potential benefit: If successful, this research could lead to a significant reduction in HIV viral load and potentially allow patients to control the virus without ongoing antiretroviral therapy.
How similar studies have gone: Previous studies have shown promise in using gene-modified cells for HIV treatment, indicating that this approach could be a significant advancement in HIV therapy.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Henrich, Timothy Jensen — University of California, San Francisco
- Study coordinator: Henrich, Timothy Jensen
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.